Skandinaviska Enskilda Banken AB publ Sells 57,000 Shares of Hologic, Inc. $HOLX

Skandinaviska Enskilda Banken AB publ reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 26.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 158,964 shares of the medical equipment provider’s stock after selling 57,000 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.07% of Hologic worth $10,355,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Hologic during the second quarter valued at approximately $180,055,000. Allspring Global Investments Holdings LLC lifted its position in Hologic by 473.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after acquiring an additional 1,405,085 shares in the last quarter. Nuance Investments LLC boosted its stake in Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after purchasing an additional 931,920 shares during the last quarter. Black Creek Investment Management Inc. boosted its stake in Hologic by 26.1% during the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after purchasing an additional 764,573 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.2%

Shares of HOLX stock opened at $74.98 on Friday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $80.31. The stock has a market cap of $16.71 billion, a P/E ratio of 31.11, a P/E/G ratio of 2.54 and a beta of 0.65. The company has a 50 day simple moving average of $71.48 and a two-hundred day simple moving average of $67.02.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the previous year, the firm posted $1.01 EPS. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HOLX. BNP Paribas downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Mizuho cut shares of Hologic from an “outperform” rating to a “neutral” rating and upped their target price for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Stephens lowered shares of Hologic from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $79.67.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.